 Moderna NASDAQ: MRNA stock is rising higher on Tuesday following the release of data from a Phase 2B cancer vaccine clinical trial. Moderna is currently testing its cancer vaccine alongside Merck Cos NYSE: MRK Keytruda immunotherapy. 